Iovance enters $450M ATM equity offering with Jefferies, replaces prior program

IOVANCE BIOTHERAPEUTICS, INC.

Company entered new Open Market Sale Agreement with Jefferies for up to $450M in at-the-market common stock sales.
Jefferies will receive commission of up to 3% of gross proceeds under the new program.
Prior ATM agreement dated November 18, 2022 was terminated concurrently.
Sales may be made through various methods including ordinary brokers' transactions on Nasdaq.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 1.0

IOVANCE BIOTHERAPEUTICS, INC. entered into Sales Agreement with Jefferies LLC valued at up to $450.0 million (effective 2023-06-16).

Action: entry
Agreement: atm program
Counterparty: Jefferies LLC
Value: up to $450.0 million
Effective: 2023-06-16

Exact text from the filing

On June 16, 2023, Iovance Biotherapeutics, Inc. (the “ Company ”) entered into a new Open Market Sale Agreement (the “ Sales Agreement ”) with Jefferies LLC (“ Jefferies ”) with respect to an at the market offering program, under which the Company may, from time to time in its sole discretion, issue and sell through Jefferies, acting as sales agent, up to $450.0 million of shares of the Company's common stock, par value $0.000041666 per share (the “ Common Shares ”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 1.0

IOVANCE BIOTHERAPEUTICS, INC. terminated Prior Sales Agreement with Jefferies LLC (effective 2023-06-16).

Action: termination
Agreement: atm program
Counterparty: Jefferies LLC
Effective: 2023-06-16

Exact text from the filing

On June 16, 2023, the Company terminated its Open Market Sale Agreement, dated November 18, 2022, with Jefferies (the “ Prior Sales Agreement ”) related to the offer and sale of shares of the Company's common stock in at-the-market offerings.

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

IOVANCE BIOTHERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-072308

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.